Clinical trials: Chronic Pulmonary Obstruction
Chronic Obstructive Pulmonary Disease
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
To demonstrate the non-inferiority of QVA149 110/50 µg o.d. to fluticasone/salmeterol 500/50 µg b.i.d. in terms of trough Forced Expiratory Volume in one second (FEV1) (mean of 23 hours 15 min and 23 hours 45 min post QVA149…
- Trial name
- NCT01709903
- Testing
- QVA149, Fluticasone/salmeterol
- Where
- 55 sites in Argentina, Chile and 2 more
- Volunteers
- 744 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
Chronic Obstructive Pulmonary Disease
A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)
A real world study to determine the effectiveness of a patient support service to aid COPD patients in their self management.
- Trial name
- Me&MyCOPD (NCT02300090)
- Testing
- Test Group, Control Group
- Where
- 23 sites in United Kingdom
- Volunteers
- 161 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.
- Trial name
- SPEED (NCT00542880)
- Testing
- Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg, Seretide Diskus (salmeterol/fluticasone) 50/500 μg
- Where
- 59 sites in Argentina, Australia and 7 more
- Volunteers
- 442 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121)
The purpose of this trial is to study the effects of roflumilast on lung function parameters indicative of hyperinflation in patients with COPD.
- Trial name
- NCT00108823
- Testing
- Roflumilast
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 550 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale
Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting
The mainstay of asthma treatment are ICSs, mostly combined with LABA. In the past decade LAMA had been accepted as an add-on treatment for patients on GINA treatment Steps 4 and 5.
- Trial name
- STRENGTH (NCT06678191)
- Testing
- BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
- Where
- 45 sites in Hungary
- Volunteers
- 800 people
- Sponsor
- Chiesi Hungary Ltd.
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168844
- Testing
- Tiotropium Inhalation Solution
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
- Trial name
- NCT01192191
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
- Where
- 35 sites in Japan
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
Sleep Apnea, Obstructive, Chronic Obstructive Pulmonary Disease
SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS
This is a prospective multipart clinical performance study to compare the ability of the SnoreSounds algorithm with polysomnography (PSG) and a type III Home Sleep Testing (HST) device to identify patients with obstructive sleep…
- Trial name
- SNORESOUNDS (NCT03288376)
- Where
- 3 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Incyphae, Inc.
Pulmonary Disease, Chronic Obstructive
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while…
- Trial name
- ENHANCE-3 (NCT07874815)
- Testing
- Ensifentrine, Standard of Care (SOC)
- Volunteers
- 2,136 people
- Sponsor
- Merck Sharp & Dohme LLC
COPD
A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Evaluate Quality Improvement and Oxygen Utilization Improvements. 1.
- Trial name
- BRVB-OCD (NCT02627599)
- Testing
- Breath Responsive Variable Bolus Oxygen Conserving Device
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- StratiHealth
Pulmonary Disease, Chronic Obstructive
Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)
Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and…
- Trial name
- NCT02172456
- Testing
- 99mTc-radiolabelled tiotropium, non-radiolabelled tiotropium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
This study compared the efficacy of indacaterol versus placebo in COPD patients classified as GOLD 2014 Patient Group B. This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient Gorup B.
- Trial name
- NCT02418468
- Testing
- Indacaterol
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease
This project is the stage of dose escalation, is was divided into single and multiple dose clinical study, This is a multi-center, randomized, double-blind, placebo-controlled , study to the safety, tolerability and…
- Trial name
- NCT06711991
- Testing
- TQC3927 powder for inhalation
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Emphysema, Acute Respiratory Distress Syndrome
Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure
A new artificial lung device has been developed that potentially provides added support to mechanical ventilation for severely damaged lungs.
- Conditions
- Emphysema, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Asthma
- Trial name
- NCT00288964
- Testing
- Hattler Respiratory Assist Catheter
- Where
- United Kingdom
- Sponsor
- Alung Technologies
Chronic Obstructive Pulmonary Disease
Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Pilot study in 15 stable male subjects with severe-to-very severe Chronic Obstructive Pulmonary Disease (COPD) to evaluate the effects of short term use of the Breathe Technologies noninvasive open ventilation (NIOV) system on…
- Trial name
- NCT01372462
- Testing
- NIOV - Room Air, NIOV - Oxygen, Nasal Cannula Oxygen
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Breathe Technologies, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Umeclidinium/vilanterol (UMEC/VI) is a combination product under development that is used for the treatment of airflow obstruction in patients with COPD.
- Trial name
- NCT01879410
- Testing
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
- Where
- 72 sites in United States, Chile and 5 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)
A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00418613
- Testing
- MK633
- Volunteers
- 266 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.